Testing the Ability of Pembrolizumab to Alter the Tumor Immune MicroEnvironment (TIME) of High Risk DCIS

Trial Profile

Testing the Ability of Pembrolizumab to Alter the Tumor Immune MicroEnvironment (TIME) of High Risk DCIS

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Jun 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
    • 19 Jun 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
    • 18 Apr 2018 Results presented at the 109th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top